Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD) as immunoadsorbent. We showed that two different immunoadsorbents, very efficiently and selectively depleted the MuSK antibodies from all tested sera, were stable during the procedure and were reusable. Furthermore, animal experiments showed that the treatment has no toxic effects to the animals. We conclude that the MuSK-ECD-mediated immunoadsorption can be used as an efficient antigen-specific therapy for MuSK-MG. Copyright © 2014 Elsevier B.V. All rights reserved.


Lamprini Skriapa, Paraskevi Zisimopoulou, Nikolaos Trakas, Eirini Grapsa, Socrates J Tzartos. Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy. Journal of neuroimmunology. 2014 Nov 15;276(1-2):150-8

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 25262156

View Full Text